Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT07004413 |
Title | Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients (FIRE-11) |
Acronym | FIRE-11 |
Recruitment | Not yet recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | Charite University, Berlin, Germany |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | DEU |